Cancers are diverse and adaptable. That is why a staggering 97% of cancer drugs in clinical trials fail to receive FDA approval. Researchers try to stay one step ahead of cancer by studying the mechanisms that lead to drug resistance, finding new drug targets, and developing novel therapies, such as immunotherapeutics. In this episode narrated by Niki Spahich, Sejal Davla from The Scientist’s Creative Services team spoke with Jason Sheltzer, an assistant professor in the Department of Genomics, Genetics, and Epigenomics and Yale Cancer Center at the Yale School of Medicine, about his work on drug resistance in cancer, chromosomal instability in cancer cells, and approaches to identify new treatment strategies.
The Scientist Speaks - Homing in on New Anticancer Targets
Jason Sheltzer discusses cancer mechanisms leading to drug resistance and new approaches to find drug targets.
Written bySejal Davla, PhD
Sejal Davla is a neuroscientist with a PhD from McGill University and a science storyteller. As a science editor for The Scientist’s Creative Services Team, she develops stories about the latest research in biology.
View Full Profile
Learn about our Editorial Policies.
| 1 min read
800-x-560-sept-tss
Image credit:800-x-560-sept-tss
Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Related Topics
Meet the Author
Sejal Davla obtained a PhD in neuroscience from McGill University, where she studied glia development and function in sleep and circadian rhythms. During this time, she worked with numerous science communication and policy organizations to advocate for open science practices. She joined The Scientist’s Creative Services Team as an assistant science editor in May 2021.
View Full Profile
Share
